Efficacy and Safety of Tocilizumab for TAO

Sponsor
Sun Yat-sen University
Study ID
NCT06087731
Phase
PHASE2
Status
Withdrawn

Conditions

  • Thyroid Associated Ophthalmopathy
  • Tocilizumab

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study aims to evaluate the efficacy and safety of tocilizumab treating Thyroid Associated Ophthalmopathy.

Key Dates

Start date
Sep 23, 2023
Status verified
Apr 2023
Primary completion
Sep 23, 2023
Completion
Sep 23, 2023

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: tocilizumab
    administrated with tocilizumab (8mg/kg) every four weeks

Primary Outcome Measure

volume and signal intensity of each extraocular muscles and soft tissue in MRI images [ Time Frame: month 1，month 3，month 6 ]

Related Studies